Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure
Authors:
- Jan GroetznerJGJan Groetzner
- Bruno MeiserBMBruno Meiser
- Peter LandwehrPLPeter Landwehr
- Lucia BuehseLBLucia Buehse
- Markus MuellerMMMarkus Mueller
- Ingo KaczmarekIKIngo Kaczmarek
- Michael VogeserMVMichael Vogeser
- Sabine DaebritzSDSabine Daebritz
- Peter UeberfuhrPUPeter Ueberfuhr
- Bruno ReichartBRBruno Reichart
- 1 February 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 77 (4) , 568-574
Abstract
Calcineurin-inhibitor (CNI)-related renal failure is a common problem after cardiac transplantation (HTx). The aim of this study was to introduce a CNI-free immunosuppressive regimen to HTx recipients with late posttransplant renal impairment and to evaluate the impact of conversion to this new immunosuppression (mycophenolate mofetil [MMF] and sirolimus [Sir]) treatment on renal function. Thirty-one HTx patients (25 men, 6 women; 0.2–14.2 years after transplantation) with CNI-based immunosuppression and a serum creatinine greater than 1.9 mg/dL were included in the study. Creatinine and cystatin levels were monitored to detect renal function. Mean patient age was 50±14 (range 19–74) years. Conversion was started with 6 mg Sir, continued with 2 mg, and the dose was adjusted to achieve target trough levels between 8 and 14 ng/mL. MMF was continued with trough level adjusted (1.5–4 μg/mL). Subsequently, the CNIs were tapered down and stopped. Clinical follow-up (first and every 3 months after conversion) included endomyocardial biopsies, echocardiography, and laboratory studies. Survival was 90% after a mean follow-up of 13±5 months. No acute rejection episode was detected during the study period. Renal function improved significantly after conversion: creatinine preconversion vs. postconversion: 3.14±0.76 mg/dL vs. 2.14±0.83 mg/dL, P =0.001. Cystatin preconversion vs. postconversion: 2.95±1.06 mg/L vs. 2.02±1.1 mg/L, P =0.01. In three patients, hemodialysis therapy was stopped completely after conversion. Graft function remained stable. Fractional shortening preconversion vs. postconversion: 36.9±6% vs. 36.4±6%. There were no serious adverse events. One patient had to be excluded because of noncompliance. Conversion from CNI-based immunosuppression to MMF and Sir in HTx patients with chronic renal failure was safe, preserved graft function, and improved renal function.Keywords
This publication has 21 references indexed in Scilit:
- Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairmentThe Journal of Heart and Lung Transplantation, 2002
- Outcome in patients with end‐stage renal disease following heart or heart–lung transplantation receiving peritoneal dialysisNephrology Dialysis Transplantation, 2001
- Long-term outcomes after cardiac transplantation: an experience based on different eras of immunosuppressive therapyThe Annals of Thoracic Surgery, 2001
- Cyclosporine verus tacrolimus in heart transplantation: an ISHLT/UNOS registry analysisThe Journal of Heart and Lung Transplantation, 2001
- Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up?Transplantation Proceedings, 2001
- Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoringThe Journal of Heart and Lung Transplantation, 1999
- SYNERGISTIC EFFECTS OF MYCOPHENOLATE MOFETIL AND SIROLIMUS IN PREVENTION OF ACUTE HEART, PANCREAS, AND KIDNEY ALLOGRAFT REJECTION AND IN REVERSAL OF ONGOING HEART ALLOGRAFT REJECTION IN THE RAT1,2Transplantation, 1998
- Treatment of end-stage renal failure after heart transplantationNephrology Dialysis Transplantation, 1998
- Renal insufficiency after heart transplantation: a case-control studyNephrology Dialysis Transplantation, 1998
- CYCLOSPORINE-ASSOCIATED END-STAGE NEPHROPATHY AFTER CARDIAC TRANSPLANTATIONTransplantation, 1997